Integer (NYSE:ITGR) Sees Large Volume Increase – Should You Buy?

Integer Holdings Co. (NYSE:ITGR) shares saw an uptick in trading volume on Tuesday . 307,111 shares traded hands during mid-day trading, a decline of 2% from the previous session’s volume of 314,283 shares.The stock last traded at $118.10 and had previously closed at $117.18.

Analysts Set New Price Targets

ITGR has been the topic of several research reports. Citigroup increased their price target on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Truist Financial raised their price target on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. KeyCorp upped their price objective on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a report on Friday, February 21st. Finally, Benchmark boosted their target price on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $149.00.

Integer Trading Up 2.0 %

The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. The firm has a market cap of $4.02 billion, a PE ratio of 35.57, a P/E/G ratio of 1.72 and a beta of 1.24. The business has a fifty day moving average price of $132.23 and a 200 day moving average price of $132.29.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The company had revenue of $449.50 million during the quarter, compared to analysts’ expectations of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. Analysts forecast that Integer Holdings Co. will post 6.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ITGR. Blue Trust Inc. raised its stake in shares of Integer by 4.4% during the fourth quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock worth $220,000 after purchasing an additional 71 shares during the last quarter. Arizona State Retirement System boosted its position in Integer by 0.9% during the fourth quarter. Arizona State Retirement System now owns 9,732 shares of the medical equipment provider’s stock worth $1,290,000 after purchasing an additional 84 shares in the last quarter. HighTower Advisors LLC grew its stake in Integer by 0.8% in the 3rd quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock valued at $1,579,000 after acquiring an additional 90 shares during the last quarter. HighPoint Advisor Group LLC increased its stake in shares of Integer by 6.4% during the 4th quarter. HighPoint Advisor Group LLC now owns 1,684 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 101 shares in the last quarter. Finally, Norden Group LLC increased its position in Integer by 7.0% during the fourth quarter. Norden Group LLC now owns 1,668 shares of the medical equipment provider’s stock worth $221,000 after buying an additional 109 shares in the last quarter. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.